[1]韦湘红,胡振斌.化肝纤方治疗乙肝肝硬化代偿期瘀血阻络证疗效机制理论探讨[J].西部中医药,2026,39(01):160-164.[doi:10.12174/j.issn.2096-9600.2026.01.27]
　WEI Xianghong,HU Zhenbin.Theoretical Discussion on the Therapeutic Mechanism of Huaganxian Prescription in the Treatment of Blood Stasis Obstructing Collaterals Pattern of Compensated HBV - related Cirrhosis[J].Western Journal of Traditional Chinese Medicine,2026,39(01):160-164.[doi:10.12174/j.issn.2096-9600.2026.01.27]
点击复制

化肝纤方治疗乙肝肝硬化代偿期瘀血阻络证疗效机制理论探讨()

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
39
期数:
2026年01期
页码:
160-164
栏目:
研究进展
出版日期:
2026-01-15

文章信息/Info

Title:
Theoretical Discussion on the Therapeutic Mechanism of Huaganxian Prescription in the Treatment of Blood Stasis Obstructing Collaterals Pattern of Compensated HBV - related Cirrhosis
作者:
韦湘红1, 胡振斌2
1.广西中医药大学，广西 南宁 530000
2.广西中医药大学第一附属医院，广西 南宁 530000
Author(s):
WEI Xianghong1, HU Zhenbin2
1.Guangxi University of Chinese Medicine, Nanning 530000, China
2.The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530000, China
关键词:
乙肝肝硬化; 化肝纤方; 代偿期; 瘀血阻络证; 机制探讨
Keywords:
HBV - related cirrhosis; Huaganxian prescription; compensatory period; blood stasis obstructing collaterals pattern; mechanism discussion
分类号:
R256.42
DOI:
10.12174/j.issn.2096-9600.2026.01.27
文献标志码:
A
摘要:
从乙肝肝硬化病因病机、化肝纤方的基本方义、药物成分药理研究及临床疗效等方面探讨化肝纤方治疗乙肝肝硬化代偿期瘀血阻络证的疗效机制，指出化肝纤方基于中医中药理论，采用活血祛瘀、益气散结的治疗法则，结合中药药理与临床经验进行化裁，用药精当，配伍严谨，契合乙肝肝硬化代偿期湿毒损伤肝脏，阻滞气机，瘀血渐生阻滞肝络的病理机制。且化肝纤方具有减少细胞外基质生成、抑制肝纤维化、保护肝脏、抗炎、抗抑郁等作用机制。
Abstract:
We discussed therapeutic mechanism of Huaganxian (hepatic fibrosis-eliminating) prescription in the treatment of blood stasis obstructing collaterals pattern of compensated HBV - related cirrhosis from the etiology and pathogenesis of the disease, basic meaning of Huaganxian prescription, pharmacological studies of drug components and clinical effects. Huaganxian prescription adopted therapeutic principles of activating blood and removing stasis, benefiting Qi and resolving massed based on TCM theory, modified in light of the pharmacology of TCM and clinical experience, with precision in medication selecton and rigor in formula composi-tion, conforming to the pathogenesis of compensated HBV - related cirrhosis: damp-toxin damaging liver, obstruc-ting Qi movement, and blocking liver collateral by chronic blood stasis. The prescription could reduce the produc-tion of extracellular matrix, inhibit hepatic fibrosis, protect liver, fight against the inflammation and depression.

相似文献/References:

[1]杨惠敏,蒋春彦.软肝汤联合阿德福韦酯治疗代偿期乙肝肝硬化42例[J].西部中医药,2017,30(12):82.
　YANG Huimin,JIANG Chunyan.Treating 42 Cases of Hepatitis B Cirrhosis at Compensatory Phase by Liver-softening Decoction Combined with Adefovir Dipivoxil[J].Western Journal of Traditional Chinese Medicine,2017,30(01):82.
[2]吕艳杭,吴姗姗,王振常,等.柔肝化纤颗粒治疗乙肝肝硬化腹水的临床疗效及对肝纤维化、氧化应激水平的影响[J].西部中医药,2021,34(03):19.[doi:10.12174/j.issn.2096-9600.2021.03.05]
　LYU Yanhang,WU Shanshan,WANG Zhenchang,et al.Curative Effects of Rougan Huaxian Granules in Treating Ascites of Hepatitis B Cirrhosis and Its Influence on the Levels of Oxidative Stress and Liver Fibrosis[J].Western Journal of Traditional Chinese Medicine,2021,34(01):19.[doi:10.12174/j.issn.2096-9600.2021.03.05]

备注/Memo

备注/Memo:
国家科技重大专项课题（2018ZX10725505-002）。韦湘红（1996—），女，硕士学位。研究方向：中医药防治肝病。
更新日期/Last Update: 2026-01-15